Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
You get to
Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor
Semaglutide, originally developed for diabetes management, showed significant weight loss results in both clinical trials and real-world settings, which attracted widespread adoption
These therapies target BDNF either by directly promoting its endogenous production (i.e., via BDNF gene therapy) or indirectly enhancing BDNF signaling and secretion in the brain (i.e., via exercise)
US$ 24.41
US$ 27.51
US$ 26.92
